CLAIMS

1. A compound having Structural Formula (I):




(I),

or a pharmaceutically acceptable salt thereof, wherein:

X is $C(R^2)$;

$R^1$ is selected from hydrogen, halo, $-(C_1-C_6$ alkyl) unsubstituted or substituted with one or more substituents independently selected from $-NR^BR^{B'}$, $-C(O)NR^BR^{B'}$, $-OR^A$, $-(C_0-C_6$ alkylene)-carbocyclyl, and $-(C_0-C_6$ alkylene) heterocyclyl, wherein $R^A$ is $C_1-C_6$ alkyl unsubstituted or substituted with one or more fluoro;

each of $R^2$, $R^3$, $R^5$ and $R^6$ is independently selected from hydrogen, halo, $-(C_1-C_6$ alkyl), $-OR^A$, $-C(O)NR^BR^{B'}$, $NR^BR^{B'}$, $S(O)_{0-2}R^C$, $-(C_0-C_6$ alkylene)-carbocyclyl, and $-(C_0-C_6$ alkylene) heterocyclyl; or

$R^2$ and $R^3$ are optionally taken together with atoms to which they are bound to form a carbocyclyl or heterocyclyl ring;

$R^4$ is selected from hydrogen, $-(C_1-C_6$ alkyl), $-(C_0-C_6$ alkylene)-carbocyclyl, and $-(C_0-C_6$ alkylene) heterocyclyl;

$R^{4'}$ is selected from hydrogen, $-(C_2-C_6$ alkyl), $S(O)_{1-2}R^C$, $-(C_0-C_6$ alkylene) carbocyclyl, $-(C_0-C_6$ alkylene) heterocyclyl, $-C(O)-(C_1-C_6$ alkyl), and $-C(O)-(C_1-C_6$ alkyl) $NR^DR^E$; or

$R^4$ and $R^{4'}$ are optionally taken together with the nitrogen atom to which they are commonly bound to form a 4-8 membered ring optionally comprising 1-2 additional heteroatoms independently selected from N, O and S;

$R^{6'}$ is selected from hydrogen, $-(C_1-C_6$ alkyl) and $-(C_3-C_6$ cycloalkyl);

each $R^A$ is independently selected from hydrogen, -($C_1$-$C_6$ alkyl), -($C_0$-$C_6$ alkylene)-carbocyclyl, -($C_0$-$C_6$ alkylene)-heterocyclyl, -C(O)-($C_1$-$C_6$ alkyl), -C(O)-($C_0$-$C_6$ alkylene)-carbocyclyl, -C(O)-($C_0$-$C_6$ alkylene)-heterocyclyl, and -C(O)N($R^D$)($R^E$);

each $R^B$ and each $R^{B'}$ is independently selected from hydrogen, -($C_1$-$C_6$ alkyl), -($C_1$-$C_6$ haloalkyl), -($C_0$-$C_6$ alkylene)-carbocyclyl, -($C_0$-$C_6$ alkylene)-heterocyclyl, -$S(O)_{1-2}$-($C_1$-$C_6$ alkyl), -$S(O)_{1-2}$-($C_0$-$C_6$ alkylene)-carbocyclyl, -$S(O)_{1-2}$-($C_0$-$C_6$ alkylene)-heterocyclyl, -C(O)-($C_1$-$C_6$ alkyl), -C(O)-($C_0$-$C_6$ alkylene)-carbocyclyl, -C(O)H, -C(O)-($C_0$-$C_6$ alkylene)-heterocyclyl, and -C(O)-($C_0$-$C_6$ alkylene)-N($R^D$)($R^E$);

each $R^C$ is independently selected from -($C_1$-$C_6$ alkyl), -($C_0$-$C_6$ alkylene)-carbocyclyl and -($C_0$-$C_6$ alkylene)-heterocyclyl; and

each $R^D$ and each $R^E$ is independently selected from hydrogen, -($C_1$-$C_6$ alkyl), -($C_0$-$C_6$ alkylene)-carbocyclyl, and -($C_0$-$C_6$ alkylene)-heterocyclyl,

wherein:

any alkyl, or alkylene portion of $R^2$, $R^3$, $R^4$, $R^{4'}$, $R^5$, $R^6$ is unsubstituted or independently substituted with one or more substituents independently selected from halo, =O, $OR^A$, $NR^BR^{B'}$, and $S(O)_{0-2}R^C$;

any alkyl or alkylene portion of $R^{6'}$, $R^A$, or $R^C$, is unsubstituted or independently substituted with one or more fluoro;

any carbocyclyl or heterocyclyl portion of any of $R^2$, $R^3$, $R^4$, $R^{4'}$, $R^5$, $R^6$, or any ring formed by taking together $R^2$ and $R^3$ or $R^4$ and $R^{4'}$ is unsubstituted or independently substituted on a carbon atom with one or more substituents independently selected from halo, =O, $C_1$-$C_4$ fluoroalkyl, $C_1$-$C_4$ alkyl, -($C_0$-$C_6$ alkylene)-($C_3$-$C_{10}$ carbocyclyl), -($C_0$-$C_6$ alkylene)-(4-13 membered heterocyclyl), $OR^A$, -($C_0$-$C_6$ alkylene)-$NR^BR^{B'}$, and $S(O)_{0-2}R^C$;

any heterocyclyl portion of any of $R^2$, $R^3$, $R^4$, $R^{4'}$, $R^5$, $R^6$, or any ring formed by taking together $R^2$ and $R^3$ or $R^4$ and $R^{4'}$ is unsubstituted or independently substituted on a substitutable nitrogen atom with $R^F$;

each $R^F$ is independently selected from -($C_1$-$C_6$ alkyl), -($C_1$-$C_6$ haloalkyl), -($C_1$-$C_6$ hydroxyalkyl), -($C_0$-$C_6$ alkylene)-carbocyclyl, -($C_0$-$C_6$ alkylene)-heterocyclyl, -$S(O)_{1-2}$-($C_1$-$C_6$ alkyl), -$S(O)_{1-2}$-($C_0$-$C_6$ alkylene)-carbocyclyl, -$S(O)_{1-2}$-($C_0$-$C_6$ alkylene)-heterocyclyl, -C(O)-($C_1$-$C_6$

~~alkyl), -C(O)-(C$_0$-C$_6$-alkylene)-carbocyclyl, -C(O)H, -C(O)-(C$_0$-C$_6$-alkylene)-heterocyclyl, -(C$_0$-C$_6$-alkylene)-C(O)$_2$-(C$_1$-C$_6$-alkyl), -(C$_1$-C$_6$-alkylene)-NR$^B$R$^{B'}$ and -C(O)N(R$^D$)(R$^E$);~~

~~any carbocyclyl or heterocyclyl portion of R$^A$, R$^B$, R$^{B'}$, R$^C$, R$^D$, R$^E$, R$^F$, any cycloalkyl portion of R$^{6'}$, or any substituent of R$^2$, R$^3$, R$^4$, R$^{4'}$, R$^5$, R$^6$ is unsubstituted or independently substituted on a carbon atom with a one or more substituents independently selected from fluoro, chloro, C$_1$-C$_4$-alkyl, C$_1$-C$_4$-fluoroalkyl, -O-C$_1$-C$_4$-alkyl, -O-C$_1$-C$_4$-fluoroalkyl, =O, -OH, -NH$_2$, -NH(C$_1$-C$_4$-alkyl), and -N(C$_1$-C$_4$-alkyl)$_2$;~~

~~any heterocyclyl portion of R$^A$, R$^B$, R$^{B'}$, R$^C$, R$^D$, R$^E$, R$^F$, or any heterocyclyl substituent of R$^2$, R$^3$, R$^4$, R$^{4'}$, R$^5$, or R$^6$ is unsubstituted or substituted on a substitutable nitrogen atom with -C$_1$-C$_4$-alkyl, or -S(O)$_{1-2}$-(C$_1$-C$_4$-alkyl); and~~

~~the compound is other than:~~



,



,



,



,



,



,






a salt of any of the foregoing.

2. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein:

each of $R^2$, $R^3$, $R^5$ and $R^6$ is independently selected from hydrogen, halo, $(C_1$-$C_6$ alkyl), $OR^A$, $C(O)NR^BR^{B'}$, $NR^BR^{B'}$, $S(O)_{0-2}R^C$, $(C_0$-$C_6$ alkylene) carbocyclyl, and $(C_0$-$C_6$ alkylene) heterocyclyl; or

$R^2$ and $R^3$ are optionally taken together with atoms to which they are bound to form a carbocyclyl or heterocyclyl ring;

$R^4$ is selected from hydrogen, $(C_1$-$C_6$ alkyl), $(C_0$-$C_6$ alkylene) carbocyclyl, and $(C_0$-$C_6$ alkylene) heterocyclyl;

$R^{4'}$ is selected from hydrogen, , $(C_2$-$C_6$ alkyl), $S(O)_{1-2}R^C$, $(C_0$-$C_6$ alkylene) carbocyclyl, $(C_0$-$C_6$ alkylene) heterocyclyl, $C(O)$ $(C_1$-$C_6$ alkyl), and $C(O)$ $(C_1$-$C_6$ alkyl) $NR^DR^E$; or

$R^4$ and $R^{4'}$ are optionally taken together with the nitrogen atom to which they are commonly bound to form a 4-8 membered ring optionally comprising 1-2 additional heteroatoms independently selected from N, O and S;

$R^{6'}$ is selected from hydrogen, $(C_1$-$C_6$ alkyl) and $(C_3$-$C_6$ cycloalkyl);

each $R^A$ is independently selected from hydrogen, $(C_1$-$C_6$ alkyl), $(C_0$-$C_6$ alkylene) carbocyclyl, $(C_0$-$C_6$ alkylene) heterocyclyl, $C(O)$ $(C_1$-$C_6$ alkyl), $C(O)$ $(C_0$-$C_6$ alkylene) carbocyclyl, $C(O)$ $(C_0$-$C_6$ alkylene) heterocyclyl, and $C(O)N(R^D)(R^E)$;

each $R^B$ and each $R^{B'}$ is independently selected from hydrogen, -($C_1$-$C_6$ alkyl), -($C_0$-$C_6$ alkylene)-carbocyclyl, -($C_0$-$C_6$ alkylene)-heterocyclyl, -$S(O)_{1-2}$-($C_1$-$C_6$ alkyl), -$S(O)_{1-2}$-($C_0$-$C_6$ alkylene)-carbocyclyl, -$S(O)_{1-2}$-($C_0$-$C_6$ alkylene)-heterocyclyl, -C(O)-($C_1$-$C_6$ alkyl), -C(O)-($C_0$-$C_6$ alkylene)-carbocyclyl, -C(O)H, -C(O)-($C_0$-$C_6$ alkylene)-heterocyclyl, and -C(O)N($R^D$)($R^E$);

each $R^C$ is independently selected from -($C_1$-$C_6$ alkyl), -($C_0$-$C_6$ alkylene)-carbocyclyl and -($C_0$-$C_6$ alkylene)-heterocyclyl; and

each $R^D$ and each $R^E$ is independently selected from hydrogen, -($C_1$-$C_6$ alkyl), -($C_0$-$C_6$ alkylene)-carbocyclyl, and -($C_0$-$C_6$ alkylene)-heterocyclyl,

wherein:

any alkyl, or alkylene portion of $R^2$, $R^3$, $R^4$, $R^{4'}$, $R^5$, $R^6$ is unsubstituted or independently substituted with one or more substituents independently selected from halo, =O, $OR^A$, $NR^BR^{B'}$, and $S(O)_{0-2}R^C$;

any alkyl or alkylene portion of $R^{6'}$, $R^A$, or $R^C$, is unsubstituted or independently substituted with one or more fluoro;

any carbocyclyl or heterocyclyl portion of any of $R^2$, $R^3$, $R^4$, $R^{4'}$, $R^5$, $R^6$, or any ring formed by taking together $R^2$ and $R^3$, or $R^4$ and $R^{4'}$ is unsubstituted or independently substituted on a carbon atom with one or more substituents independently selected from halo, =O, $C_1$-$C_4$ fluoroalkyl, $C_1$-$C_4$ alkyl, $C_3$-$C_{10}$ carbocyclyl, a 4-13 membered heterocyclyl, $OR^A$, $NR^BR^{B'}$, and $S(O)_{0-2}R^C$;

any heterocyclyl portion of any of $R^2$, $R^3$, $R^4$, $R^{4'}$, $R^5$, $R^6$, or any ring formed by taking together $R^2$ and $R^3$, or $R^4$ and $R^{4'}$ is unsubstituted or independently substituted on a substitutable nitrogen atom with $R^F$;

each $R^F$ is independently selected from -($C_1$-$C_6$ alkyl), -($C_0$-$C_6$ alkylene)-carbocyclyl, -($C_0$-$C_6$ alkylene)-heterocyclyl, -$S(O)_{1-2}$-($C_1$-$C_6$ alkyl), -$S(O)_{1-2}$-($C_0$-$C_6$ alkylene)-carbocyclyl, -$S(O)_{1-2}$-($C_0$-$C_6$ alkylene)-heterocyclyl, -C(O)-($C_1$-$C_6$ alkyl), -C(O)-($C_0$-$C_6$ alkylene)-carbocyclyl, -C(O)H, -C(O)-($C_0$-$C_6$ alkylene)-heterocyclyl, and -C(O)N($R^D$)($R^E$);

any carbocyclyl or heterocyclyl portion of $R^A$, $R^B$, $R^{B'}$, $R^C$, $R^D$, $R^E$, $R^F$, any cycloalkyl portion of $R^{6'}$, or any substituent of $R^2$, $R^3$, $R^4$, $R^{4'}$, $R^5$, $R^6$ is unsubstituted or independently substituted on a carbon atom with a one or more substituents independently selected from fluoro, chloro, $C_1$-$C_4$-alkyl, $C_1$-$C_4$-fluoroalkyl, -O-$C_1$-$C_4$-alkyl, -O-$C_1$-$C_4$-fluoroalkyl, =O, -OH, $-NH_2$, -NH($C_1$-$C_4$-alkyl), and -N($C_1$-$C_4$-alkyl)$_2$; and

any heterocyclyl portion of $R^A$, $R^B$, $R^{B'}$, $R^C$, $R^D$, $R^E$, $R^F$, or any heterocyclyl substituent of $R^2$, $R^3$, $R^4$, $R^{4'}$, $R^5$, or $R^6$ is unsubstituted or substituted on a substitutable nitrogen atom with -$C_1$-$C_4$-alkyl, or -$S(O)_{1-2}$-($C_1$-$C_4$-alkyl).

3. The compound of claim 1 or 2, wherein each of $R^5$, $R^6$ and $R^{6'}$ is hydrogen.

4. The compound of any one of claims 1 to 3, wherein:

$R^4$ is selected from hydrogen and -($C_1$-$C_6$-alkyl);

$R^{4'}$ is selected from hydrogen, -($C_2$-$C_6$-alkyl) unsubstituted or substituted with one or more substituents independently selected from hydroxy and halo, -($C_3$-$C_6$-cycloalkyl), -C(O)-($C_1$-$C_6$-alkyl), -C(O)-($C_1$-$C_6$-alkylene)-N($R^D$)($R^E$), and $S(O)_{1-2}R^C$; or

$R^4$ and $R^{4'}$ are taken together with the nitrogen atom to which they are commonly bound to form a 4-6 membered ring optionally comprising 1-2 additional heteroatoms independently selected from N, O and S;

$R^C$ is -($C_1$-$C_6$-alkyl); and

each of $R^D$ and $R^E$ is independently selected from hydrogen and -($C_1$-$C_6$-alkyl).

5. The compound of claim 4, wherein:

$R^4$ is selected from hydrogen and -($C_1$-$C_6$-alkyl);

$R^{4'}$ is selected from hydrogen, -($C_2$-$C_6$-alkyl), -($C_3$-$C_6$-cycloalkyl), -C(O)-($C_1$-$C_6$-alkyl), -C(O)-($C_1$-$C_6$-alkylene)-N($R^D$)($R^E$), and $S(O)_{1-2}R^C$;

$R^C$ is -($C_1$-$C_6$-alkyl); and

each of $R^D$ and $R^E$ is independently selected from hydrogen and -($C_1$-$C_6$-alkyl).

6. The compound of claim 5, wherein:

$R^4$ is selected from hydrogen, methyl, ethyl and propyl; and

$R^{4'}$ is selected from hydrogen, ethyl, propyl, cyclopropyl, $-C(O)CH_3$, $-C(O)CH_2N(CH_3)_2$, and $-S(O)_2CH_3$.

7. The compound of any one of claim 1 to 6, wherein $R^3$ is selected from hydrogen and $N(R^B)(R^{B'})$, wherein $R^B$ is hydrogen.

8. The compound of claim 1, wherein $R^1$ is selected from hydrogen, halo, $(C_1\text{-}C_6$ alkyl) optionally substituted with one or more substituents $-OR^A$, wherein $R^A$ is $C_1\text{-}C_6$ alkyl optionally substituted with one or more fluoro.

9. The compound of claim 8, wherein $R^1$ is selected from hydrogen, fluoro, chloro, $OCH_3$, $OCF_3$, $N(CH_3)_2$ and $NHCH_3$.

10. The compound of claim 9, wherein $R^1$ is selected from hydrogen, fluoro, chloro, and $OCF_3$.

11. The compound of any one of claims 1 to 10, wherein

$R^2$ is $(C_0\text{-}C_6$ alkylene) heterocyclyl optionally substituted on a nitrogen atom with $(C_1\text{-}C_6$ alkyl); $(C_0\text{-}C_6$ alkylene) carbocyclyl; or $(C_1\text{-}C_6)$alkyl substituted with $NR^BR^{B'}$.

12. The compound of claim 11, wherein $R^2$ is pyrrolidinyl optionally substituted on a nitrogen atom with $C_1\text{-}C_4$ alkyl or benzyl.

13. The compound of any one of claims 1 to 10, wherein:

$R^2$ and $R^3$ are taken together with the atoms to which they are bound to form a nitrogen-containing heterocyclyl.

14. The compound of claim 13, wherein $R^2$ and $R^3$ are taken together with the atoms to which they are bound to form



wherein "~~2~~" represents a point of attachment to the carbon atom bound to $R^2$; "~~3~~" represents a point of attachment to the carbon atom bound to $R^3$; and f is 0 or 1.

15. The compound of any one of claims 1 to 12, wherein:

$R^3$ is selected from hydrogen and $-N(R^B)(R^{B'})$, wherein $R^B$ is hydrogen and $R^{B'}$ is $-C(O)-(C_0-C_6\text{ alkylene})\text{-heterocyclyl}$ or $-C(O)-(C_0-C_6\text{ alkylene})-N(R^D)(R^E)$.



16. The compound of claim 15, wherein $R^3$ is selected from hydrogen and .

17. A compound selected from any one of the following compounds:

| Compound No. | Compound Structure | Compound No. | Compound Structure | Compound No. | Compound Structure |
|---|---|---|---|---|---|
| S7-14-1-A (diastereomer A) S7-14-1-B (diastereomer B) |  | S7-14-2-A (diastereomer A) |  | S7-14-3-A (diastereomer A) |  |
| S8-4-1 |  | S8-4-2 |  | S8-4-3 |  |
| S9-4-1 |  | S9-5-1 |  | S9-5-2 |  |
| S9-5-3 |  | S9-5-4 |  | S9-5-5 |  |
| S9-5-6 |  | S10-4-1 (single diastereomer) |  | S10-4-2 (single diastereomer) |  |
| S10-4-3 (single diastereomer) |  | S11-3-1 |  | S11-3-2 |  |

| Compound No. | Compound Structure | Compound No. | Compound Structure | Compound No. | Compound Structure |
|---|---|---|---|---|---|
| S11-3-3 |  | | | | |
| S13-5-1 |  | S13-5-2 |  | S14-8-1 |  |
| S14-8-2 |  | S14-8-3-A (diastereomer A) S14-8-3-B (diastereomer B) |  | S15-10-1 |  |
| S15-10-2 |  | S15-10-3-A (diastereomer A) S15-10-3-B (diastereomer B) |  | S16-7-1 (single diastereomer) |  |
| S16-7-2 (single diastereomer) |  | S16-7-3 (single diastereomer) |  | S16-7-4 (single diastereomer) |  |
| S16-7-5 (single diastereomer) |  | S16-7-6 (single diastereomer) |  | | |
| S18-5-1-1 |  | S18-5-1-2 |  | | |
| S18-5-2-1 |  | S18-5-2-2 |  | S19-7-1-B (diastereomer B) |  |
| S19-7-2 |  | S19-7-3-A (diastereomer A) S19-7-3-B (diastereomer B) |  | S19-7-4-A (diastereomer A) S19-7-4-B (diastereomer B) |  |
| S19-7-5-A (diastereomer A) S19-7-5-B (diastereomer B) |  | S19-7-6 |  | S19-7-7-A (diastereomer A) S19-7-7-B (diastereomer B) |  |
| S20-4-1 (single diastereomer) |  | S20-4-2 (single diastereomer) |  | S20-4-3 (single diastereomer) |  |
| S20-4-4 (single diastereomer) |  | S21-5-1 |  | S21-5-2 |  |
| S21-5-3 |  | S21-5-4 |  | | |

~~or a pharmaceutically acceptable salt thereof.~~

~~18. A pharmaceutical composition comprising a pharmaceutically acceptable carrier or diluent and a compound of any one of Claims 1-17.~~

~~19. A compound of any one of Claims 1-17, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of Claim 18 for use in therapy.~~

~~20. A compound of any one of Claims 1-17, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of Claim 18 for use in the treatment or prevention of an infection or colonization in a subject.~~

~~21. The compound, or the pharmaceutically acceptable salt thereof, or the pharmaceutical composition of Claim 20, wherein the infection is caused by an organism that grows intracellularly as part of its infection process.~~

~~22. The compound, or the pharmaceutically acceptable salt thereof, or the pharmaceutical composition of Claim 20, wherein the infection is caused by a Gram-positive organism.~~

~~23. The compound, or the pharmaceutically acceptable salt thereof, or the pharmaceutical composition of Claim 22, wherein the Gram-positive organism is selected from the class Bacilli; phylum Actinobacteria; and class Clostridia.~~

~~24. The compound, or the pharmaceutically acceptable salt thereof, or the pharmaceutical composition of Claim 23, wherein the class Bacilli organism is selected from *Staphylococcus* spp., *Streptococcus* spp., *Enterococcus* spp., *Bacillus* spp., and *Listeria* spp.~~

~~25. The compound, or the pharmaceutically acceptable salt thereof, or the pharmaceutical composition of Claim 23, wherein phylum Actinobacteria organism is selected from *Propionibacterium* spp., *Corynebacterium* spp., *Nocardia* spp., and *Actinobacteria* spp.~~

~~26. The compound, or the pharmaceutically acceptable salt thereof, or the pharmaceutical composition of Claim 23, wherein class Clostridia organism is selected from *Clostridium* spp.~~

~~27. The compound, or the pharmaceutically acceptable salt thereof, or the pharmaceutical composition of Claim 22, wherein the infection is caused by a Gram-negative organism.~~

~~28. The compound, or the pharmaceutically acceptable salt thereof, or the pharmaceutical composition of Claim 27, wherein the Gram-negative organism is selected from the group consisting of *Enterobactericeae, Bacteroidetes, Vibrionaceae*, *Pasteurellaceae*, *Pseudomonadaceae*, *Neisseriaceae, Rickettsiae*, *Moraxellaceae* any species of *Proteeae, Acinetobacter* spp., *Helicobacter* spp., and *Campylobacter* spp.~~

~~29. The compound, or the pharmaceutically acceptable salt thereof, or the pharmaceutical composition of Claim 20, wherein the infection is caused by an organism selected from order Rickettsiales and order Chlamydiales.~~

~~30. The compound, or the pharmaceutically acceptable salt thereof, or the pharmaceutical composition of Claim 20, wherein the infection is caused by an organism selected from the phylum Chlamydiae and phylum Spriochaetales.~~

~~31. The compound, or the pharmaceutically acceptable salt thereof, or the pharmaceutical composition of Claim 30, wherein the phylum Spriochaetales organism is selected from *Borrelia* spp. and *Treponema* spp.~~

~~32. The compound, or the pharmaceutically acceptable salt thereof, or the pharmaceutical composition of Claim 20, wherein the infection is caused by an organism selected from the class Mollicutes.~~

~~33. The compound, or the pharmaceutically acceptable salt thereof, or the pharmaceutical composition of Claim 32, wherein the class Mollicutes organism is selected from *Mycoplasma* spp.~~

~~34. The compound, or the pharmaceutically acceptable salt thereof, or the pharmaceutical composition of Claim 33, wherein *Mycoplasma* spp. is *Mycoplasma pneumoniae.*~~

~~35. The compound, or the pharmaceutically acceptable salt thereof, or the pharmaceutical composition of Claim 20, wherein the infection is caused by an organism selected from *Legionella* spp. and *Mycobacterium* spp.~~

~~36. The compound, or the pharmaceutically acceptable salt thereof, or the pharmaceutical composition of Claim 35, wherein the *Mycobacterium* spp is *Mycobacterium tuberculosis.*~~

~~37. The compound, or the pharmaceutically acceptable salt thereof, or the pharmaceutical composition of Claim 20, wherein the infection is caused by more than one organism.~~

~~38. The compound, or the pharmaceutically acceptable salt thereof, or the pharmaceutical composition of Claim 20, wherein the infection is caused by an organism resistant to one or more antibiotics.~~

~~39. The compound, or the pharmaceutically acceptable salt thereof, or the pharmaceutical composition of Claim 20, wherein the infection is caused by an organism resistant to tetracycline or any member of first and second generation of tetracycline antibiotics.~~

~~40. The compound, or the pharmaceutically acceptable salt thereof, or the pharmaceutical composition of Claim 20, wherein the infection is caused by an organism resistant to methicillin or any antibiotic in the β-lactam class.~~

~~41. The compound, or the pharmaceutically acceptable salt thereof, or the pharmaceutical composition of Claim 40, wherein the β-lactam class is selected from second, third and fourth-generation cephalosporins.~~

~~42. The compound, or the pharmaceutically acceptable salt thereof, or the pharmaceutical composition of Claim 20, wherein the infection is caused by an organism resistant to a quinolone or fluoroquinolone.~~

~~43. The compound, or the pharmaceutically acceptable salt thereof, or the pharmaceutical composition of Claim 20, wherein the infection is caused by an organism resistant to tigecycline.~~

~~44. The compound, or the pharmaceutically acceptable salt thereof, or the pharmaceutical composition of Claim 20, wherein the infection is caused by an organism resistant to tetracycline.~~

~~45. The compound, or the pharmaceutically acceptable salt thereof, or the pharmaceutical composition of Claim 20, wherein the infection is caused by an organism resistant to methicillin.~~

~~46. The compound, or the pharmaceutically acceptable salt thereof, or the pharmaceutical composition of Claim 20, wherein the infection is caused by an organism resistant to vancomycin.~~

~~47. The compound, or the pharmaceutically acceptable salt thereof, or the pharmaceutical composition of Claim 20, wherein the infection is caused by an organism resistant to an antimicrobial peptide or a biosimilar therapeutic treatment.~~

~~48. The compound, or the pharmaceutically acceptable salt thereof, or the pharmaceutical composition of Claim 22, wherein the Gram-positive organism is selected from *S. aureus*, CoNS, *S. pneumoniae*, *S. pyogenes*, *S. agalactiae*, *E. faecalis* and *E. faecium*.~~

~~49. The compound, or the pharmaceutically acceptable salt thereof, or the pharmaceutical composition of Claim 27, wherein the Gram-negative organism is selected from selected from *H. influenza, M. catarrhalis* and *Legionella pneumophila*.~~

~~50. A compound of any one of Claims 1-17, or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition of Claim 18 for use in the treatment or prevention of a respiratory infection in a subject.~~

~~51. The compound, or the pharmaceutically acceptable salt thereof, or the pharmaceutical composition of Claim 50, wherein the respiratory infection is Community-Acquired Bacterial Pneumonia (CABP).~~

~~52. The compound, or the pharmaceutically acceptable salt thereof, or the pharmaceutical composition of Claim 50 or Claim 51, wherein the respiratory infection is caused by a bacterium selected from *S. aureus*, *S. pneumoniae*, *S. pyogenes*, *H. influenza, M. catarrhalis* and *Legionella pneumophila.*~~

~~53. A compound of any one of Claims 1-17, or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition of Claim 18 for use in the treatment or prevention of a skin infection in a subject.~~

~~54. The compound, or the pharmaceutically acceptable salt thereof, or the pharmaceutical composition of Claim 53, wherein the skin infection is an acute bacterial skin and skin structure infection (ABSSSI).~~

~~55. The compound, or the pharmaceutically acceptable salt thereof, or the pharmaceutical composition of Claim 53 or Claim 54, wherein the skin infection is caused by a bacterium selected from *S. aureus*, CoNS, *S. pyogenes*, *S. agalactiae*, *E. faecalis* and *E. faecium*.~~

1. A compound represented by any one of the following structural formulas:

(S10-4-1)



(S10-4-2)



or a pharmaceutically acceptable salt of any of the foregoing.

2. A pharmaceutical composition comprising a pharmaceutically acceptable carrier or diluent and a compound of claim 1 or a pharmaceutically acceptable salt thereof.

3. A compound represented by the following structural formula:

(S10-4-1)



or a pharmaceutically acceptable salt thereof.

4. A pharmaceutical composition comprising a pharmaceutically acceptable carrier or diluent and a compound of claim 3 or a pharmaceutically acceptable salt thereof.